US 11,053,305 B2
Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptide
Michael Steven Curtis, Waltham, MA (US); Michael Storek, Cambridge, MA (US); Shelia Marie Violette, Lexington, MA (US); Susan L. Kalled, Concord, MA (US); Kelly C. Fahnoe, Waltham, MA (US); Cheng Ran Huang, Belmont, MA (US); Ellen Garber Stark, Cambridge, MA (US); Frederick Robbins Taylor, Milton, MA (US); Justin Andrew Caravella, Cambridge, MA (US); and Vernon Michael Holers, Denver, CO (US)
Assigned to Q32 Bio Inc., Cambridge, MA (US)
Filed by Q32 Bio Inc., Cambridge, MA (US)
Filed on Jan. 24, 2020, as Appl. No. 16/752,074.
Application 16/752,074 is a continuation of application No. PCT/US2019/065741, filed on Dec. 11, 2019.
Claims priority of provisional application 62/778,014, filed on Dec. 11, 2018.
Prior Publication US 2020/0181249 A1, Jun. 11, 2020
Int. Cl. C07K 16/18 (2006.01); A61P 13/12 (2006.01); A61K 38/17 (2006.01); C07K 14/47 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 38/1725 (2013.01); A61P 13/12 (2018.01); C07K 14/472 (2013.01); C07K 2317/51 (2013.01); C07K 2317/565 (2013.01); C07K 2319/00 (2013.01)] 35 Claims
 
1. A fusion protein construct comprising:
(1) an antibody or an antigen binding fragment thereof that specifically binds to complement protein 3d (c3d), wherein the antibody or antigen binding fragment thereof comprises:
(a) a heavy chain comprising three heavy chain complementarity determining regions (CDR-H1, CDR-H2, CDR-H3), wherein the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 29, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 260, and the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 31, and,
(b) a light chain comprising three light chain complementarity determining regions (CDR-L1, CDR-L2, CDR-L3), wherein the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 32, the CDR-L2 comprises the amino acid sequence of SEQ ID NO: 33, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 34, and
(2) a complement modulator polypeptide, wherein the complement modulator polypeptide comprises CR1 or a biologically active fragment thereof.